Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye bleeding study aims to predict who sees better after gas procedure

NCT ID NCT07427160

Knowledge-focused Sponsor: Marco Mazzola Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is for people with age-related macular degeneration who have bleeding under the retina. Researchers want to see if the type of abnormal blood vessel affects how well vision recovers after a gas bubble procedure to move the blood. About 60 participants will be followed for 6 months to measure vision and eye structure changes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
pneumatic displacement (a procedure using gas to move blood under the retina)
What this could lead to
If successful, this could help doctors predict which patients with macular bleeding will recover better vision after this procedure, leading to more personalized treatment.
What could go wrong
This is a small, early-stage observational study with only 60 participants, so results may not apply to all patients. The procedure itself carries risks like infection or retinal detachment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of Caucasian patients, aged 50 years or older, diagnosed with submacular hemorrhage (SMH) secondary to macular neovascularization (MNV). All participants underwent pneumatic displacement treatment at the Multizonal Ophthalmology Unit of the Provincial Agency for Healthcare Services (APSS) in Trento and Rovereto, Italy, between December 1, 2016, and May 31, 2023.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients undergoing pneumatic displacement (PD) for submacular hemorrhage (SMH), secondary to macular neovascularization (MNV) * Age 50 years or older at the time of SMH diagnosis * Caucasian ethnicity * SMH involving the central or internal ring of the Early Treatment Diabetic Retinopathy Study (ETDRS) grid (within a 3 mm circumference centered on the fovea) * SMH dimensions equal to or greater than one papillary diameter * Pneumatic displacement treatment performed within 36 hours of SMH diagnosis Exclusion Criteria: * SMH estimated to be present for more than 15 days at the time of diagnosis * SMH secondary to conditions other than MNV * Presence of proliferative diabetic retinopathy in the study eye * Aphakia in the study eye * Inadequate pupillary dilation, media opacities, or other impediments to retinal imaging * Previous pneumatic displacement procedures for SMH in the study eye * Ocular surgery in the 8 weeks preceding the pneumatic displacement intervention * Follow-up duration of less than 6 months following the procedure

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMD - age-related macular degeneration are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

age-related macular degeneration macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AMD - age-related macular degeneration

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ospedale Santa Chiara Di Trento

    RECRUITING

    Trento, Trento, 38122, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.